February 21, 2024 12:17pm
CRSP trading up at $3.73 at +4.73% at $82.45 <so far>
CRSP reported its first profit in 10 quarters on Wednesday,
The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.
Has entered into an investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics’ 30-day volume-weighted average price.
The Bottom Line: after a net income for Q4 /23 - why not ... as FY&23 rang in a net loss of $136,050 M or -$1.94
Q4/23 revenue also topped projections at $201.2 million.
Now that CRSP and Vertex (VRTX) are working to commercialize Casgevy, Crispr's earlier-stage pipeline efforts more closely watched. CEO Kulkarni said Crispr began testing two treatments for cardiovascular diseases in people last year.
CRSP is also testing cancer treatments "which have the potential to be best-in-class cell therapies for the treatment of both liquid and solid tumors," he said in a written statement. He sees the next 12 to 18 months as being particularly "catalyst-rich" for the company. <IBD>
Debt: $241.59 M
52-week range: $90.18 and a low of $37.55
Shares outstanding: 83.36 M
Float: 78.42 M shares
Short ratio: 7.89%
